While apparently helpful concepts such as “best interests” appear to have the virtue of simplicity, they are really place holders for the communication, time and listening that’s required to understand what truly matters to patients and others involved in healthcare. When we know what matters to a patient, we can have confidence that we have a “legitimate” view of what’s important to them. Two papers in this issue of the Journal of Medical Ethics explore different ways in which values can be legitimised and applied consistently in healthcare.

When a patient can no longer say what it is that matters to them and a significant decision needs to be made, the values that will inform what should happen next need to be legitimised in some way. Common ways of doing that include proxy decision makers or advanced directives. In this issue of the Journal of Medical Ethics, we have a “legitimate” view of what’s important to them. Two papers in this issue of the Journal of Medical Ethics explore different ways in which values can be legitimised and applied consistently in healthcare.

The importance of patient values for clinical practice is a central pillar of medical ethics, and it’s also important for prioritisation and the healthcare system more generally. Health economic tools such as QALYs are invaluable for making comparisons between the cost utility of health care services, and they are used extensively in countries such as the United Kingdom, Canada, Australia and New Zealand. They’re used less extensively in the United States, where it seems the implication that they measure the quality of a person’s life and attach a financial value to it, led to their use not being permitted by some federal legislation.1 Indispensable as such tools are in many countries, we are generally accepted as one element of sound prioritisation and that they need to be supplemented by other considerations such as rarity of the condition, how many therapeutic options there are for that condition and fairness more generally.

The British National Institute for Clinical Excellence (NICE) was one of the first institutions to augment cost utility analysis with methods to incorporate other values.2 Their original social values framework and use of a Citizen’s Jury to inform prioritisation was criticised at the time in the JME3 primarily on the grounds of whether it lived up to its aim to follow Daniels and Sabin’s “accountability for reasonableness” framework.4 Jonathen Michaels expresses the concern that current attempts to introduce social values into prioritisation run the risk of a “distorted assessment of value.”5 A commitment to the Daniels and Sabin requirement for “transparency” in prioritisation decision-making would have helped resolve a number of the distortions he identifies. He explains how since the NICE social values document, other agencies have adopted “...additional value elements such as innovation, rarity, burden of disease and end-of-life treatments...” As he observes, while such values seem relevant, how can they be legitimised for public policy and how should they be weighted? Michaels offers a taxonomy of the values that have been proposed for evaluating health outcomes and raises challenges that each one presents. For him, legitimising these values requires a commitment to demonstrating their “relevance”, another procedural requirement from the accountability for reasonableness framework. Central among these is the requirement that values are applied consistently across different decision-making and the opportunity costs of decisions are part of their application. One of the central challenges for medical ethics is legitimising value and although that is often contentious, it is vital for the task of reaching well justified ethical decisions.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

ORCID iD
John McMillan http://orcid.org/0000-0002-7507-1861

REFERENCES